RCS - PureTech Health PLC - PRTC'S Vedanta Expands Leadership Team

Puretech HealthAnnouncement

23/07/2024 12:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240723:nRSW3647Xa&default-theme=true

RNS Number : 3647X  PureTech Health PLC  23 July 2024

23 July 2024

PureTech Health plc

 

PureTech Founded Entity Vedanta Biosciences Expands Leadership Team and
Appoints Head of Commercial

Appointments support ongoing Phase 2 COLLECTiVE202 trial of VE202, pivotal
Phase 3 RESTORATiVE303 trial of VE303 and planning for commercial stage
activity

PureTech Health plc (https://puretechhealth.com/) (Nasdaq: PRTC, LSE: PRTC)
("PureTech" or the "Company"), a clinical-stage biotherapeutics
company dedicated to changing the lives of patients with devastating
diseases, noted that its Founded Entity, Vedanta Biosciences
(https://www.vedantabio.com/) , a clinical-stage biopharmaceutical company
developing medicines for the treatment of gastrointestinal diseases, today
announced three appointments to its leadership team. Christof Marré, a
seasoned biopharma marketing leader, joins the company as Senior Vice
President and Head of Commercial. In addition, Steven Shiff, M.D., a
pharmaceutical executive and physician specializing in gastroenterology, has
been appointed as SVP, Clinical Research; and Jack Kyte has been promoted to
SVP, Human Resources.

 

The full text of the announcement from Vedanta is as follows:

 

Vedanta Biosciences Expands Leadership Team and Appoints Head of Commercial

Appointments support ongoing Phase 2 COLLECTiVE202 trial of VE202, pivotal
Phase 3 RESTORATiVE303 trial of VE303 and planning for commercial stage
activity

CAMBRIDGE, MA, July 23, 2024 - Vedanta Biosciences
(https://www.vedantabio.com/) , a clinical-stage biopharmaceutical company
developing medicines for the treatment of gastrointestinal diseases, today
announced three appointments to its leadership team. Christof Marré, a
seasoned biopharma marketing leader, joins the company as Senior Vice
President and Head of Commercial. In addition, Steven Shiff, M.D., a
pharmaceutical executive and physician specializing in gastroenterology, has
been appointed as SVP, Clinical Research; and Jack Kyte has been promoted to
SVP, Human Resources.

 

"I am delighted to welcome Christof and Steve to the team," said Bernat Olle,
Ph.D., Co-Founder and Chief Executive Officer of Vedanta Biosciences. "The
expertise that Christof, Steve, and Jack bring are vital to our next phase of
growth as we execute our ongoing pivotal Phase 3 RESTORATiVE303 trial of VE303
for C. difficile infection and Phase 2 COLLECTiVE202 trial of VE202 for
ulcerative colitis, and establish our commercial function."

 

Christof Marré brings almost three decades of experience as a biopharma
marketing leader and strategist, and most recently served as VP of Marketing
& Pipeline Planning at Alpine Immune Sciences, recently acquired by Vertex
Pharmaceuticals. At Alpine, he established the company's Commercial function,
including building out capabilities in market research, competitive
intelligence, healthcare practitioner marketing & patient advocacy, and
driving indication prioritization and valuation within the company's
Immunology portfolio. Earlier in his career, Mr. Marré was involved with
multiple successful product launches at both established and emerging
biopharma companies. He holds a Master of Science degree in Economics from The
London School of Economics and Political Science (LSE).

 

Steven Shiff, M.D., is a gastroenterologist and clinical executive with over
20 years of experience in research and industry R&D. Dr. Shiff was most
recently SVP and Head of Clinical Development at Intercept Pharmaceuticals,
where he oversaw design and implementation of the company's global clinical
development strategy focused on rare and serious liver diseases, including
supporting an NDA filing. Previously, he served as VP, Clinical Development,
and GI Therapeutic Area Head at Allergan for 14 years, in which capacity he
led global clinical development of the company's GI pipeline and marketed GI
product portfolio. Dr. Shiff spent the first 13 years of his career as a
practicing physician and professor, initially at The Rockefeller University
and later at Rutgers-Robert Wood Johnson Medical School.

 

Jack Kyte has served as Vice President and Head of Human Resources at Vedanta
since 2020, following more than a decade of multi-industry HR experience. Mr.
Kyte is responsible for developing and executing Vedanta's people strategy in
alignment with the organization's current and anticipated future needs and
overseeing its human resources function both internally and with external
partners.

 

About Vedanta Biosciences

Vedanta Biosciences  (https://www.vedantabio.com/) is a clinical-stage
biopharmaceutical company developing medicines for the treatment of
gastrointestinal diseases. The company's lead assets are potential
first-in-class oral therapies - VE303, in a Phase 3 registrational trial for
prevention of recurrent C. difficile infection, and VE202, in a Phase 2 trial
for treatment of ulcerative colitis. Vedanta's pipeline has been built using
the company's industry-leading product engine for the development of therapies
based on defined consortia of bacteria grown from pure clonal cell banks. The
product engine, supported by broad foundational intellectual property,
includes one of the largest libraries of bacteria isolated from the human
microbiome, vast clinical datasets, proprietary capabilities in consortium
design, and end-to-end CGMP manufacturing capabilities at commercial launch
scale.

 

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life
to new classes of medicine to change the lives of patients with devastating
diseases. The Company has created a broad and deep pipeline through its
experienced research and development team and its extensive network of
scientists, clinicians and industry leaders that is being advanced both
internally and through its Founded Entities. PureTech's R&D engine has
resulted in the development of 29 therapeutics and therapeutic candidates,
including two that have received both U.S. FDA clearance and European
marketing authorization and a third (KarXT) that has been filed for FDA
approval. A number of these programs are being advanced by PureTech or its
Founded Entities in various indications and stages of clinical development,
including registration enabling studies. All of the underlying programs and
platforms that resulted in this pipeline of therapeutic candidates were
initially identified or discovered and then advanced by the PureTech team
through key validation points.

 

For more information, visit www.puretechhealth.com
(http://www.puretechhealth.com/)  or connect with us on X (formerly Twitter)
@puretechh.

 

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that are or may be forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. All statements contained in this press release that do not relate to
matters of historical fact should be considered forward-looking statements,
including without limitation those related to the VE303 and VE202 development
programs, development plans and potential benefits to patients and our future
prospects, developments and strategies. The forward-looking statements are
based on current expectations and are subject to known and unknown risks,
uncertainties and other important factors that could cause actual results,
performance and achievements to differ materially from current expectations,
including, but not limited to, those risks, uncertainties and other important
factors described under the caption "Risk Factors" in our Annual Report on
Form 20-F for the year ended December 31, 2023, filed with the SEC and in our
other regulatory filings. These forward-looking statements are based on
assumptions regarding the present and future business strategies of the
Company and the environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press release.
Except as required by law and regulatory requirements, we disclaim any
obligation to update or revise these forward-looking statements, whether as a
result of new information, future events or otherwise.

 

Contact:

PureTech

Public Relations

publicrelations@puretechhealth.com (mailto:publicrelations@puretechhealth.com)

Investor Relations

IR@puretechhealth.com (mailto:IR@puretechhealth.com)

 

UK/EU Media

Ben Atwell, Rob Winder

+44 (0) 20 3727 1000

puretech@fticonsulting.com (mailto:puretech@fticonsulting.com)

 

US Media

Nichole Bobbyn

+1 774 278 8273

nichole@tenbridgecommunications.com
(mailto:nichole@tenbridgecommunications.com)

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRADZGZNNZVGDZM